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MinireviewDendritic Cells as Vectors
for Therapy
(type 1), IL-4 (type 2), or IL-10 (regulatory T cells). Such
control can be influenced by the subset of DC and the
type and duration of the maturation signals they receive.
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Evidence is starting to accumulate for the role of DCs inDallas, Texas
the induction of immunological tolerance. A provocative2 Department of Dermatology
recent example is the observation that immature DCsUniversity of Erlangen, Nuremberg
are not simply ignored by the immune system, but canNuremberg
lead to tolerance by inducing IL-10 producing, regula-Germany
tory T cells (Dhodapkar et al., 2001; Jonuleit et al., 2000).
Therefore, the biology of DCs offer several targets for
the control of cellular immunity.Vaccines against infectious diseases are the success
Immunization strategies in cancer and infectious dis-story of immunology. They have eradicated smallpox
eases may frequently have as a common denominatorand spared countless people from tetanus, measles,
the targeting of DCs. However, it will be critical to con-polio, and hepatitis. Consequently, there is a hope for
sider the function of distinct DC subsets (Figure 1), andthe generation of effective cancer vaccine(s). However,
induction of appropriate maturation and migration. If thecancer vaccines should be therapeutic in early (including
vaccine goes to the “wrong” DC subset and/or failspremalignant) and advanced cancer and should induce
to induce its maturation, there might be no protectivecellular and not just humoral immunity.
immunity, and possibly the induction of tolerance. TheVaccines are composed of antigen(s) and adjuvant(s).
functions of DC subsets will be considered below. WeAdjuvants play a critical role in determining the quantity
will emphasize recent studies that exploit DCs gener-
and quality of the immune response to the antigen. Iden-
ated ex vivo, charged with antigen, and injected back
tification of appropriate adjuvants represents a universal
into animals or humans to manipulate immunity. Obser-
problem in vaccine development. For example, alumi-
vations from these studies together with advances in
num hydroxide (AlOH), currently the standard adjuvant
DC biology will teach us how to manipulate DCs in vivo.
for prophylactic vaccination to infectious diseases in- Vaccination with DCs to Improve Immunity
duces type 2 T cell (Th2) and antibody responses. How- Inaba and colleagues demonstrated that the injection
ever, Th2 immunity and antibody responses may be of DCs, charged with antigen ex vivo, could sensitize
harmful. Classic examples include Dengue and respira- normal mice to protein antigens (Steinman, 1991). This
tory syncytial virus (RSV) vaccines that cause higher seminal work also suggested that using DCs directly as
morbidity upon subsequent exposure to the virus in vac- a vaccine might best circumvent the problem of variable
cinated (RSV) or naturally infected (Dengue) patients. in vivo DC targeting. The immunogenicity of antigens
Furthermore, AlOH does not induce Th1 and cytotoxic delivered on DCs has now been demonstrated in human
T cell (CTL) responses that are necessary for effective studies. Indeed, single s.c. immunization of healthy vol-
antitumor immunity. Other adjuvants such as QS-21, unteers with 2–4  106 antigen-loaded mature mono-
GM-CSF, and incomplete Freund’s adjuvant have per- cyte-derived DCs rapidly expanded CD8 and CD4 T
mitted, in some instances, specific CD8 T cell re- cell immunity. A single boost several months later led
sponses when injected with tumor antigens; these re- to expansion of CTL with increased affinity against viral
sponses were, however, detectable only after in vitro peptide, an observation never made with any other vac-
restimulation (Bendandi et al., 1999; Rosenberg et al., cination strategy so far (Dhodapkar et al., 2000).
1998; Simon et al., 2001). Dendritic cells (DCs), the topic There is a large body of literature involving animal
of this review, are “Nature’s adjuvants” and, as such, models of tumor immunity in which DCs loaded with
represent an essential component of any vaccination tumor associated antigens (TAA) are able to induce pro-
strategy. tective antitumor responses. When tested, DCs can be
DCs were originally discovered as antigen presenting superior to other vaccination strategies (Gilboa, 1999).
cells critical for the induction of primary T cell-depen- There also are reports in which DC immunization pro-
dent immune responses (Steinman, 1991). Immature duces significant therapeutic immunity to established
DCs in peripheral tissues, the Langerhans cell in the tumors. A number of trials have now utilized TAA-loaded
skin being the first example, can capture antigen(s) and DCs as vaccines in humans. Some clinical and immune
can sense “danger” signals (pathogens, tissue damage, responses (T cell proliferation and DTH) without any
and local inflammation), which trigger their maturation. significant toxicity have been observed in early studies
DCs process captured or intracellularly produced anti- (Hsu et al., 1996; Nestle et al., 1998). More recent DC
vaccination studies put further emphasis on the elicitedgen(s) into peptides, migrate via afferent lymphatics to
immune responses and have included control antigenslymph nodes, and present MHC-peptide complexes to
for CD4 and CD8 T cell responses. The latter helpnaive T cells (Banchereau et al., 2000; Steinman, 1991).
to verify that the DCs are immunogenic, and that theDCs also control the type of immune response, i.e.,
patient’s immune system is competent to mount an im-cytokines produced by helper or cytotoxic T cells: IFN-
mune response. The Erlangen group demonstrated that
T cell immunity to both control antigens (viral peptide3 Correspondence: j.banchereau@baylordallas.edu [J.B.]; schuler@
derma.med.uni-erlangen.de [G.S.] and bacterial protein) and melanoma peptide can be
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Figure 2. DC-Based Vaccines: Parameters to Monitor
granules but expressing coagulation factor XIIIa. These
two subsets also emerge in cultures of stem cells with
GM-CSF and TNF (Caux et al., 1996). While both sub-
sets can induce naı¨ve CD4 T cell proliferation, only
interstitial DCs produce IL-10 and can induce the differ-
entiation of naı¨ve B cells into immunoglobulin-secreting
plasma cells. While no unique function has yet beenFigure 1. Subsets of Human Dendritic Cells Used in Clinical Trials
formally attributed to LCs, there are hints they may be
Blood DCs, mobilized by FLT3 ligand, contain both CD11cmyeloid
particularly efficient activators of cytotoxic CD8 TDC and CD11c- plasmacytoid DC. Most studies to date have been
cells. The majority of clinical studies to date have beencarried out with DC made by culturing monocytes with GM-CSF
and IL-4. These preparations contain cells that resemble intDCs and carried out with ex vivo generated monocyte-derived
are devoid of LCs. These DCs are immature and require exogenous DC (Banchereau et al., 2000), which resemble a single
factors (CD40 ligand or macrophage cytokines) for maturation. DCs subset, i.e., interstitial DCs. Another example of DC sub-
can also be generated by culturing CD34 HPC with GM-CSF and sets is evident in fresh human blood, each representing
TNF- that permits to obtain two DC subsets: LCs and intDC. Adding
a small fraction (0.3%) of the mononuclear cells. OneIL-4 to CD34 cultures with GM-CSF/TNF skews differentiation to-
terminology for these subsets is CD11c myeloid DCs,ward intDCs.
and CD11c- plasmacytoid DCs. The CD11c cells are
thought to be similar to monocyte derived DCs, while
the CD11c- plasmacytoid cells are distinct in their ca-induced, even in patients with advanced stage IV mela-
noma, by vaccination with antigen-pulsed, mature mono- pacity to make very large amounts of IFN , but much
lower amounts of IL-12. IFN- and IL-12 are two cyto-cyte-derived DC (Thurner et al., 1999). Furthermore, when
these DCs were loaded with MHC class II binding mela- kines that are part of the innate response to many patho-
gens, and they in turn influence many other aspects ofnoma peptides, strong tumor-specific Th1 responses
were elicited. IFN- secreting Th1 cells are likely to be cell-mediated immunity. The efficacy of these distinct
human DC subsets will need to be compared in clinicalcritical for more effective and long-lasting anti-tumor
immunity. The Dallas group has demonstrated that studies.
The Optimal DC Maturation State and Stimulus. Imma-CD34 stem cell-derived DCs, pulsed with control anti-
gens and multiple melanoma peptides, induce primary ture DCs are weak immunogens. Indeed, the Erlangen
group has observed that intranodal injection of imma-and recall immune responses detectable directly in the
blood in patients with stage IV melanoma. It was ob- ture DCs does not lead to significant immune responses,
contrary to the intranodal injection of mature DCs in theserved that the level of immune responses in the blood
correlated with early outcome at the tumor sites, thus same patient. Immature DCs can be tolerogenic. Indeed,
injection of immature DCs in healthy volunteers leadsproviding further stimulus for the idea that the measure-
ment of immune responses in the blood helps evaluate to the inhibition of CD8 T cell immunity to viral peptide
with the appearance of peptide-specific IL-10 producingvaccine efficacy. Many prior studies have reported some
responses in the blood, but often in the minor fraction of T cells (Dhodapkar et al., 2001). In contrast, mature DCs
(triggered for instance by a mix of macrophage productsthe vaccinated cancer patients, or only after prolonged
restimulation with antigen in culture. Although the new such as IL-1/IL-6/TNF/PGE2) induce functionally su-
perior CD8 T cells and polarize CD4 T cells towardresults with antigen-bearing DCs are encouraging, DC
vaccination is at an early stage, and several parameters IFN- production. Thus, DC maturation is a critical pa-
rameter for the use of these cells in active immunizationneed to be established (Figure 2).
Parameters of Dendritic Cell Vaccines of patients. It will be important, therefore, to identify
stimuli that trigger an equally effective maturation pro-The Subsets of DC. The concept of distinct DC subsets
in humans (Figure 1) came from analyses of skin DCs, gram in the various human DC subsets.
DCs Dose, Frequency, and Route of Injections. In hu-DCs generated in vitro by culture of CD34 stem cells,
and blood DC precursors (Banchereau et al., 2000). Hu- man trials published so far, the DCs were usually given
at 2–4 week intervals, and at doses between 4–40 millionman skin contains epidermal Langerhans cells (LCs),
characterized by the expression of CD1a and by Birbeck without striking differences in results. In vitro studies
on human T cell activation by DCs would predict thatgranules, and interstitial (dermal) DCs, lacking Birbeck
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MHC class I and class II epitopes and lead to a diverse
immune response involving many clones of CD4 T
cells and CTL are needed. These include: recombinant
proteins, exosomes (vesicles rich in MHC/peptide com-
plexes and heat shock proteins), viral vectors, plasmid
DNA, or RNA transfection (Fong and Engelman, 2000;
Gilboa, 1999). Yet another way is to exploit the capacity
of DC to present peptides from phagocytosed dead
tumor cells on both MHC class I and II molecules (Lars-
son et al., 2001). Tumor death may unravel subdominant
or cryptic epitopes which, when processed and pre-
sented by DC, may either reach the proper activation
threshold for memory T cells or lead to priming of naı¨ve
T cells. We would predict that in advanced metastaticFigure 3. Loading Antigens on Dendritic Cells
disease, using tumor cells as antigen source will be
particularly helpful, while defined antigens would be bet-
ter for the adjuvant/minimal residual disease setting,higher doses of DCs given more frequently should pro-
following, for instance, removal of a high-risk primaryvide more intense and durable TCR triggering and thus
melanoma or resection of lymph node metastasis.promote T cell priming and polarization. However, fre-
Vaccine Efficacy and the Quality of Immune Re-quent stimulation might cause activation-induced death
sponse. A difficult aspect of immunotherapy protocolsof T cells. Also, the induced CTL may kill booster DCs
is the identification of immunologic markers that willand thus reduce efficacy. Yet, fully mature DCs seem
permit prediction of clinical efficacy. While the ultimateresistant to CTL lysis.
efficacy of cancer vaccine should be measured by theOther important factors are the route of injection and
duration of disease free survival, or at least the time tothe migration of DCs from the injection site. While anti-
disease progression, these end points require sufficientlygen-loaded DCs may prime T cell responses regardless
long follow-up. Hence, the necessity for “surrogate mark-of the route of injection, the quality of responses may
ers” that would be predictive of clinical outcome. Progressbe affected by it, with predominant Th1 responses after
with vaccines against infectious diseases depended oni.d. and intralymphatic administration, but unpolarized
measuring antibody responses as “surrogate markers”;T cell and antibody responses upon i.v. administration
hence, progress with vaccines against cancer may be(Fong et al., 2001). In this way, one can investigate the
advanced by detailed measurement of elicited T cellrequirements, for example, of improving migration at the
responses in the blood.level of specific chemokines like CCL19 and CCL21 that
The quality of the induced immunity is important. Theinteract with CCR7 on maturing DCs.
measurement of antigen-specific CD8 T cells, usingA question that has yet to be addressed is the duration
MHC-tetramers, helps to quantify antigen-specific re-
of DC-based vaccination against cancer. How long shall
sponses but additional data are needed to assess func-
we keep immunizing patients in whom vaccine induces
tional activity. Cytotoxic T cell function is often evalu-
immune responses and disease stabilization? Prelimi-
ated on peptide-pulsed target cells, but it will be
nary results from the Dallas group show that some of valuable to assess recognition of endogenously ex-
the patients who had a partial response to DC therapy pressed antigens using tumor cell lines and, if possible,
after the initial 4 injections experienced further tumor primary tumor cells. More studies are needed to com-
regression after 4 additional vaccines. Possibly, consoli- pare response in the blood with that in the tumor. Skew-
dation vaccine therapy should be lifelong, and may re- ing of T cell phenotype needs to be considered as well.
quire adjunctive immune therapies such as cytokines to For example, the differential expression of CCR7 and
support T cell memory. CD45 isoforms may help characterize the functional sta-
Source, Preparation, and Antigen Loading Strategy. tus of antigen-specific T cells, i.e., CCR7 T cells (cen-
Several systems have been employed to load DCs with tral memory) will most likely migrate to lymph nodes
TAA (Gilboa, 1999) (Figure 3). Loading MHC class I mole- while the shift toward CCR7- phenotype (effector mem-
cules with peptides derived from defined antigens is ory) should be associated with migration to the tissue
most commonly used, and is also applied to recently and possibly faster differentiation into CTL capable of
identified MHC class II helper epitopes. Although impor- killing tumor cells. Other immune effectors also need to
tant for “proof of concept” studies, the use of peptides be taken into account including CD4 T cells, NKT and
has limitations coming from (1) their restriction to a given NK cells, as well as B cells. For instance, IFN- produc-
HLA type, (2) the limited number of defined TAA, and ing CD4 T cells can inhibit tumor-induced angiogen-
(3) the induction of a restricted repertoire of T cell clones esis. Induction of NKT cells that kill a wide spectrum
less able to control tumor antigen variation. Further- of tumor cells or NK cells that recognize MHC class I
more, quantity and longevity of peptide loading is diffi- deficient tumor cells could be desirable, yet caution
cult to control; the use of antibodies to MHC class I/pep- must be taken with regard to the cytokines that they
tide complexes may help in this aspect. This could also produce. Indeed, IL-13-producing NKT cells may inhibit
help determine the relationship between MHC-peptide CTL-mediated tumor elimination and favor tumor pro-
density and magnitude/affinity of induced T cell re- gression (Terabe et al., 2000). Finally, B cells may inhibit
sponses, and to standardize vaccines in large multi- the induction of T cell-mediated tumor immunity by com-
peting with DCs for uptake of tumor-derived antigenscenter trials. Alternative strategies that provide both
Cell
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(Qin et al., 1998). Yet, in the active immunization setting, zation with ex vivo generated DC has proven feasible,
there may be desirable humoral responses and we cer- and permits the enhancement as well as the dampening
tainly need to learn more about the types of humoral of antigen-specific immune responses in man. These ex
immunity induced by the different DC subsets. vivo strategies should help identify the parameters for
There are concerns that repeated immunization with DC targeting in vivo. Today’s studies are also consider-
DCs carries the risk of developing autoimmunity, partic- ing the relationship of DCs to the correction of patho-
ularly when targeting shared tumor antigens. DC-based logic or undesired immune responses, like allergic and
active immunization will clarify this issue, including the autoimmune diseases, graft rejection, and graft versus
potential value of eliciting a strong response of limited host disease.
duration to an antigen shared by the tumor and self
Selected Readingtissue.
In Vivo Manipulation of Dendritic Cells:
Banchereau, J., Briere, F., Caux, C., Davoust, J., Lebecque, S., Liu,The Targeted Vaccines
Y., Pulendran, B., and Palucka, K. (2000). Ann Rev Immunol 18,
Vaccination with ex vivo generated DCs is not feasible 767–812.
for large-scale immunization, either in cancer or in infec- Bendandi, M., Gocke, C.D., Kobrin, C.B., Benko, F.A., Sternas, L.A.,
tious diseases, e.g., malaria. Thus, there is a need to Pennington, R., Watson, T.M., Reynolds, C.W., Gause, B.L., Duffey,
develop strategies that can provide a robust protective/ P.L., et al. (1999). Nat. Med. 5, 1171–1177.
therapeutic immune response of optimal type with mini- Caux, C., Vanbervliet, B., Massacrier, C., Dezutter-Dambuyant, C.,
de Saint-Vis, B., Jacquet, C., Yoneda, K., Imamura, S., Schmitt, D.,mal amounts of vaccine and limited boosting. Research
and Banchereau, J. (1996). J. Exp. Med. 184, 695–706.in this area may benefit from the ability to (1) mobilize
Dhodapkar, M.V., Krasovsky, J., Steinman, R.M., and Bhardwaj, N.large numbers of DCs in vivo (DC-poietins) and (2) deliver
(2000). J Clin Invest 105, R9–R14.mobilized DCs to antigens and activation molecules (“in-
Dhodapkar, M.V., Steinman, R.M., Krasovsky, J., Munz, C., andtelligent missile”).
Bhardwaj, N. (2001). J. Exp. Med. 193, 233–238.DC-poietins are the cytokines that mobilize DCs in
Fong, L., and Engelman, E. (2000). Ann. Rev. Immunol. 18, 245–273.vivo: they either increase their numbers (G-CSF, GM-
Fong, L., Brockstedt, D., Benike, C., Wu, L., and Engleman, E.G.CSF, and FLT3 ligand) or activate them (IFN-) (Pulen-
(2001). J. Immunol. 166, 4254–4259.dran et al., 2001). These cytokines also mobilize other
Gilboa, E. (1999). Immunity 11, 263–270.immune effectors, for instance neutrophils (G-CSF, GM-
Hsu, F.J., Benike, C., Fagnoni, F., Liles, T.M., Czerwinski, D., Taidi,CSF), macrophages (GM-CSF), and NK cells (Flt3-L).
B., Engleman, E.G., and Levy, R. (1996). Nat. Med. 2, 52–58.Therefore, they can be expected to boost both the non-
Jonuleit, H., Schmitt, E., Schuler, G., Knop, J., and Enk, A.H. (2000).antigen-specific innate immunity and the antigen-spe-
J. Exp. Med. 192, 1213–1222.cific adaptive immunity. Indeed, administration of FLT3
Larsson, M., Fonteneau, J.F., and Bhardwaj, N. (2001). Trends Immu-ligand to mice enhances vaccine immunogenicity (in an
nol. 22, 141–148.
HIV model) as well as protects the mice against viral
Le Bon, A., Schiavoni, G., D’Agostino, G., Gresser, I., Belardelli, F.,rechallenge (in a Herpes virus model). IFN- has long
and Tough, D.F. (2001). Immunity 14, 461–470.
been recognized for its immunomodulatory activity,
Nestle, F.O., Alijagic, S., Gilliet, M., Sun, Y., Grabbe, S., Dummer,
though its adjuvancy was only recently assigned to in R., Burg, G., and Schadendorf, D. (1998). Nat. Med. 4, 328–332.
vivo DC activation (Le Bon et al., 2001).
Pulendran, B., Banchereau, J., Maraskovsky, E., and Maliszewski,
DCs may be targeted in vivo by “intelligent missile,” C. (2001). Trends Immunol. 22, 41–47.
a generic vaccine equipped with (1) the immunogens, Qin, Z., Richter, G., Schuler, T., Ibe, S., Cao, X., and Blankenstein,
the optimal antigenic preparations that can be targeted T. (1998). Nat. Med. 4, 627–630.
to desired MHC molecules; (2) DC activation molecules Rosenberg, S.A., Yang, J.C., Schwartzentruber, D.J., Hwu, P., Marin-
and specific ligands that would permit targeting of the cola, F.M., Topalian, S.L., Restifo, N.P., Dudley, M.E., Schwarz, S.L.,
desired DC subset. One might take advantage of mole- Spiess, P.J., et al. (1998). Nat. Med. 4, 321–327.
cules that bind to pattern recognition receptors, like the Simon, R.M., Steinberg, S.M., Hamilton, M., Hildesheim, A., Khleif,
S., Kwak, L.W., Mackall, C.L., Schlom, J., Topalian, S.L., and Berzof-Toll-like receptors (TLRs), through which the immune
sky, J.A. (2001). J. Clin. Oncol. 19, 1848–1854.system senses microbial products and/or tissue dam-
Steinman, R.M. (1991). Annu. Rev. Immunol. 9, 271–296.age. For example, CpG oligonucleotides can activate
DCs in vivo while heat shock proteins can both activate Terabe, M., Matsui, S., Noben-Trauth, N., Chen, H., Watson, C.,
Donaldson, D.D., Carbone, D.P., Paul, W.E., and Berzofsky, J.A.DCs and chaperone the peptide. Furthermore, as the
(2000). Nat. Immunol. 1, 515–520.TLRs are differentially expressed on DC subsets, their
Thurner, B., Haendle, I., Roder, C., Dieckmann, D., Keikavoussi, P.,ligands could serve as targeting molecules; and (3) mole-
Jonuleit, H., Bender, A., Maczek, C., Schreiner, D., von den Driesch,cules determining the quality and the type of the immune
P., et al. (1999). J. Exp. Med. 190, 1669–1678.response, for instance, chemokines attracting naı¨ve T
cells, costimulatory molecules, as well as type 1/type 2
skewing molecules.
Conclusions
DCs are an attractive target for therapeutic manipulation
of the immune system, to enhance insufficient immune
responses, in infectious diseases and cancer, or attenu-
ate excessive immune responses, in allergy and autoim-
munity. However, the complexity of the DC system
brings about the necessity for its rational manipulation
to achieve protective or therapeutic immunity. Immuni-
